Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alk-Abello ASCHIX:ALKBC 91 Debt-to-EBITDA is 0.16 as of Mar. 2026, which is 87% below its 10-year median of 1.24. GuruFocus rates CHIX:ALKBC with a GF Score™ of 91/100 and a GF Value™ of kr208.85 (Modestly Overvalued). Among 291 Biotechnology companies, Alk-Abello AS ranks better than 76.63% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Alk-Abello AS's Debt-to-EBITDA or its related term are showing as below:
CHIX:ALKBc'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.19 Med: 1.24 Max: 4.82
Current: 0.19
During the past 13 years, the highest Debt-to-EBITDA Ratio of Alk-Abello AS was 4.82. The lowest was 0.19. And the median was 1.24.
CHIX:ALKBc's Debt-to-EBITDA is ranked better than 76.63% of 291
companies
in the Biotechnology industry
Industry Median: 1.14
vs CHIX:ALKBc: 0.19
Alk-Abello AS (CHIX:ALKBc) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Alk-Abello AS Debt-to-EBITDA Related Terms
Alk-Abello AS Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Alk-Abello AS's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:ALKBC vs VRTX, REGN, ALNY: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Alk-Abello AS's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alk-Abello AS Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Alk-Abello AS's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Alk-Abello AS (CHIX:ALKBC) has a Debt-to-EBITDA of 0.16 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alk-Abello AS. This is 87% below median its historical median of 1.24. Over the past decade, Alk-Abello AS's Debt-to-EBITDA has ranged from 0.19 to 4.82. According to the industry distribution chart, Alk-Abello AS ranks #68 out of 291 companies in the Biotechnology industry, placing it in the top 23.4%.
Is Alk-Abello AS's Debt-to-EBITDA too high?
Alk-Abello AS's current Debt-to-EBITDA of 0.16 is 87% below median its 10-year median of 1.24. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 4.82. The Biotechnology industry median Debt-to-EBITDA is 1.14. Alk-Abello AS's value of 0.16 is 86% below this industry median. Based on the distribution chart, Alk-Abello AS ranks #68 out of 291 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Alk-Abello AS has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alk-Abello AS's Debt-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alk-Abello AS ranks #68 out of 291 companies for Debt-to-EBITDA. This places Alk-Abello AS in the top 23% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.14. Alk-Abello AS's value of 0.16 is 86% below this benchmark. Historically, Alk-Abello AS's own Debt-to-EBITDA has ranged from 0.19 to 4.82 over the past decade. While the company's 10-year median is 1.24 vs. the industry median of 1.14, Alk-Abello AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.14, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alk-Abello AS's current Debt-to-EBITDA of 0.16 is 86% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Alk-Abello AS. For the Biotechnology industry, the median Debt-to-EBITDA is 1.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alk-Abello AS's current Debt-to-EBITDA is 0.16, which is 87% below median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alk-Abello AS stock overvalued right now?
Based on GuruFocus' analysis, Alk-Abello AS (CHIX:ALKBC) is currently considered Modestly Overvalued. The stock's GF Value™ is kr208.85, compared to a current price of kr256.30 — trading 22.7% above its estimated fair value. The current Debt-to-EBITDA is 0.16, which is 87% below median its 10-year median of 1.24 and 86% below the Biotechnology industry median of 1.14. Alk-Abello AS's overall GF Score™ is 91/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Alk-Abello AS (CHIX:ALKBC), the current Debt-to-EBITDA is 0.16 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alk-Abello AS (CHIX:ALKBC) Overvalued in 2026?
Based on GuruFocus' analysis, Alk-Abello AS stock appears to be overvalued.
The current stock price of kr256.30 is trading 22.7% above its estimated GF Value™ of kr208.85.
GuruFocus considers Alk-Abello AS to be Modestly Overvalued.
Key valuation signals for CHIX:ALKBC:
Debt-to-EBITDA: 0.16 (87% below median its 10-year median of 1.24)
GF Value™: kr208.85 vs. price of kr256.30 (22.7% above fair value)
Industry Position: 86% below the Biotechnology median (#68 of 291)
No single metric tells the full story. See the CHIX:ALKBC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.
91GF Score
Get the complete analysis for CHIX:ALKBC
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:ALKBC has been successfully added to your 
